English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 
Nexstim Plc Launches Presence in Asia with Distribution Agreement of its SmartFocus(TM) TMS system to Access Hong Kong Market
Oct 03, 2018 20:00 HKT
Trees' species and age affect carbon emissions
Sep 25, 2018 19:00 HKT
FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome
Sep 25, 2018 18:00 HKT
Protecting rice plants by exploiting their natural defences
Sep 05, 2018 18:00 HKT
NANOBIOTIX half year results for the six months ended June 30, 2018
Sep 05, 2018 00:30 HKT
Too hot for rice?
Aug 13, 2018 18:00 HKT
Indonesian Sufism rejects radical Islam
Aug 02, 2018 23:00 HKT
Anti-ulcer benefits of honey investigated
Aug 01, 2018 09:00 HKT
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank
Jul 27, 2018 07:00 HKT
Autolus Announces Pricing of Initial Public Offering
Jun 22, 2018 10:00 HKT
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3
Jun 22, 2018 09:00 HKT
NANOBIOTIX' Management Statement on Recent Share Price Variation
Jun 06, 2018 22:00 HKT
Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States
May 09, 2018 09:00 HKT
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers
May 04, 2018 09:00 HKT
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States
Apr 20, 2018 22:10 HKT
LEH PHARMA LTD.: Company Update
Apr 18, 2018 20:30 HKT
Tusk Therapeutics presents data on to its anti-CD25 programme at AACR Annual Meeting 2018
Apr 18, 2018 20:00 HKT
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway
Apr 18, 2018 09:00 HKT
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy
Apr 17, 2018 08:00 HKT
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab
Apr 11, 2018 09:00 HKT
Next >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: